Fig. 3

Potentials and challenges of inclisiran in current lipid lowing therapies. The individual variability in response to statins/ezetimibe and poor treatment adherence to daily administration remain challenging issues in primary care. PCSK9 monoclonal antibodies provide a consistent reduction in LDL-C levels, but poor adherence due to subcutaneous injection every 2- or 4-weeks and high cost are barrier. Robust and durable reduction in LDL-C with inclisiran has the potential to improve both large variability in LDL-C levels and poor treatment adherence, on the other hand, there are some challenges such as high cost, lack of cardiovascular outcome data, and longer-term safety over 5 years. CV outcomes cardiovascular outcomes, PCSK9 mAbs monoclonal antibodies